BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11405507)

  • 1. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
    Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
    Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control of spirometry: a lesson from the BRONCUS trial.
    Pellegrino R; Decramer M; van Schayck CP; Dekhuijzen PN; Troosters T; van Herwaarden C; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Eur Respir J; 2005 Dec; 26(6):1104-9. PubMed ID: 16319343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
    Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
    Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
    Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
    Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the clinical phenotype of symptomatic chronic airways disease by hierarchical cluster analysis and two-step cluster analyses].
    Ning P; Guo YF; Sun TY; Zhang HS; Chai D; Li XM
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):679-83. PubMed ID: 27586974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
    Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
    Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
    Stav D; Raz M
    Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
    Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
    COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
    Dransfield MT; Kunisaki KM; Strand MJ; Anzueto A; Bhatt SP; Bowler RP; Criner GJ; Curtis JL; Hanania NA; Nath H; Putcha N; Roark SE; Wan ES; Washko GR; Wells JM; Wendt CH; Make BJ;
    Am J Respir Crit Care Med; 2017 Feb; 195(3):324-330. PubMed ID: 27556408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
    Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.